High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis
the study conducted to evaluate the efficacy and safety of high-dose furmonertinib (160 mg qd) combined with bevacizumab and pemetrexed intrathecal chemotherapy in NSCLC patients with EGFR mutations and meningeal metastases.
Non-small Cell Lung Cancer Metastatic
DRUG: furmonertinib
Intracranial progression-free survival, The time from receipt of study treatment to intracranial tumor PD or to death due to any cause,whichever came first,, The time from receipt of study treatment to intracranial tumor PD or to death due to any cause,whichever came first, assessed up to 24 months
systemic progression-free survival, The time from receipt of study treatment to systemic PD or to death due to any cause,whichever came first,, The time from receipt of study treatment to systemic PD or to death due to any cause,whichever came first, assessed up to 24 months.|intracranial objective response rate, The number and percentage of objective response (PR+CR) of intracranial tumor at each time point after treatment, The number and percentage of objective response (PR+CR) of intracranial tumor at each time point after treatment, through study completion, an average of 12 months.|overall survival, The time interval between enrollment and death from any cause, The time interval between enrollment and death from any cause,,whichever came first, assessed up to 24 months.|safety and tolerability, adverse events will be reported and graded according to the National Cancer Institute (NCI) CTCAE version 5.0., adverse events will be reported and graded according to the National Cancer Institute (NCI) CTCAE version 5.0.,assessed up to 24 months.
the study conducted to evaluate the efficacy and safety of high-dose furmonertinib (160 mg qd) combined with bevacizumab and pemetrexed intrathecal chemotherapy in NSCLC patients with EGFR mutations and meningeal metastases.